Cervical Cancer Prevention (NTAGI, FOGSI & WHO Guidelines)
📈 Prevention Engine: Synthesises individualised HPV vaccination eligibility, precise dose scheduling, and cervical cancer screening recommendations based on current Indian (NTAGI/FOGSI) and global standards.
Patient Demographics & History
Immunological Status
Ensure accurate selection, as immune compromise fundamentally alters the required vaccine dosing schedule regardless of age.
Vaccination Eligibility
-
-
Required Doses
-
-
1. Vaccination Action Plan
2. Cervical Screening Pathway (FOGSI/WHO)
📚 Academic Pearls & Pathophysiology
1. Pathophysiology: Why 2 Doses vs. 3 Doses?
The immune system's response to the HPV Virus-Like Particles (VLPs) is highly age-dependent. In early adolescence (ages 9–14), the naive immune system generates a profoundly robust B-cell memory response. Clinical trials proved that two doses in a 10-year-old produce significantly higher antibody titres than three doses in a 20-year-old. Once a patient reaches 15 years of age (or if they are immunocompromised), their immune geometry requires the traditional 3-dose prime-boost-boost schedule (0, 1-2, 6 months) to ensure long-term durable immunity.
2. Clinical Pitfall: The "Already Active" Fallacy
⚠ Malpractice Trap: A major barrier in India is withholding the vaccine from women who are already sexually active or who have an abnormal Pap smear, assuming it is "too late." This is clinically incorrect. The vaccine covers multiple oncogenic strains (e.g., 16, 18, 31, 33, 45, 52, 58). Exposure to one strain does NOT mean the patient is infected with all strains. Vaccination remains highly protective against the strains they have not yet encountered.
3. Clinical Pitfall: Screening Abandonment
⚠ Safety Alert: Vaccination is NOT a substitute for screening. The nonavalent vaccine covers strains responsible for ~90% of cervical cancers, meaning 10% of oncogenic strains remain uncovered. Fully vaccinated women must continue routine FOGSI/WHO-directed cervical screening (Pap smear or HPV DNA testing) according to age-based algorithms.
4. Illness Scripts: HPV Vaccines in India
Vaccine Type
Strains Covered
Clinical Utility
Bivalent (Cervarix)
16, 18
Protects against ~70% of cervical cancers. Does not protect against anogenital warts.
Quadrivalent (Gardasil / Cervavac)
16, 18, 6, 11
Protects against cervical cancer AND anogenital warts (strains 6, 11). Cervavac is the highly cost-effective indigenous Indian vaccine.
Nonavalent (Gardasil-9)
16, 18, 6, 11, 31, 33, 45, 52, 58
Broadest coverage. Protects against ~90% of cervical cancers and anogenital warts.
5. The WHO "90-70-90" Global Strategy
The WHO mandate to eliminate cervical cancer by 2030 rests on three pillars:
90% of girls fully vaccinated with HPV vaccine by age 15.
70% of women screened with a high-performance test by 35 years of age, and again by 45.
90% of women identified with cervical disease receive treatment.
Abbreviations: HPV (Human Papillomavirus) · NTAGI (National Technical Advisory Group on Immunisation) · FOGSI (Federation of Obstetric and Gynaecological Societies of India) · WHO (World Health Organization) · VLP (Virus-Like Particle) · HIV (Human Immunodeficiency Virus)
Algorithm References & Evidence Base
World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper, December 2022. Wkly Epidemiol Rec. 2022;97(50):645-672.
Meisner B, et al. FOGSI Good Clinical Practice Recommendations for Cervical Cancer Screening. 2023 Updates.
National Technical Advisory Group on Immunisation (NTAGI) 17th Meeting Recommendations (2022): HPV vaccine inclusion in the Universal Immunisation Programme (UIP).
Sankaranarayanan R, et al. HPV Vaccination and Screening: IARC India Trial. Lancet Oncol. 2022.
How to Cite This Tool
AMA Style:
Umakanth S. HPV Vaccination & Screening Pathway. MEDiscuss. Published 2026. Accessed .
Vancouver Style:
Umakanth S. HPV Vaccination & Screening Pathway [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:
